Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease

Clinical Chemistry

Volumn 56, Issue 10, 2010, Pages 1535-1543

  Lin, Jing Ping ^a   Vitek, Libor ^b   Schwertner, Harvey A ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCC2 PROTEIN; ANTIOXIDANT; BILIRUBIN; BILIVERDIN; BIOLOGICAL MARKER; CD40 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE; HEME OXYGENASE 2; INTERCELLULAR ADHESION MOLECULE 1; ORGANIC ANION TRANSPORTER 2; PADGEM PROTEIN; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTERY CALCIFICATION; ARTERY DISEASE; BILIRUBIN BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DEATH; CHROMOSOME 12P; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENE CONTROL; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; METABOLIC SYNDROME X; MORTALITY; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; STROKE; UPREGULATION; WEIGHT REDUCTION; BLOOD; CALCINOSIS; DISEASE PREDISPOSITION; GENETICS; PERIPHERAL VASCULAR DISEASE; SERUM;

BILIRUBIN; BIOLOGICAL MARKERS; BODY MASS INDEX; CALCINOSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SUSCEPTIBILITY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PERIPHERAL VASCULAR DISEASES; SERUM; STROKE;

EID: 77957735569     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.151043     Document Type: Review

References (79)

1. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alphatocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994;269:16712-9. (Pubitemid 24200431)
2. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987;84:5918-22.
3. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996;51:859-62. (Pubitemid 26096296)
4. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002;160:449-56. (Pubitemid 34159340)
5. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci U S A 2009;106:5171-6.
6. Yesilova Z, Serdar M, Ercin CN, Gunay A, Kilciler G, Hasimi A, et al. Decreased oxidation susceptibility of plasma low density lipoproteins in patients with Gilbert's syndrome. J Gastroenterol Hepatol 2008;23:1556-60.
7. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007;43:1-57. (Pubitemid 44960959)
8. Mazzone GL, Rigato I, Ostrow JD, Bossi F, Bortoluzzi A, Sukowati CH, et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009;386:338-44.
9. Tapan S, Dogru T, Tasci I, Ercin CN, Ozgurtas T, Erbil MK. Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis? Clin Biochem 2009;42:791-5.
10. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994;40:18-23. (Pubitemid 24050206)
11. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008;198:1-11.
12. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:250-5.
13. Schwertner HA. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis 1998;136:383-7.
14. Schwertner HA, Fischer JR Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 2000;150:381-7.
15. Tanaka M, Fukui M, Tomiyasu K, Akabame S, Nakano K, Hasegawa G, et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 2009;206:287-91.
16. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009;40:3422-7.
17. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008;28:166-72.
18. Rantner B, Kollerits B, Anderwald-Stadler M, Klein-Weigel P, Gruber I, Gehringer A, et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008;54:851-7. (Pubitemid 351671602)
19. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 2001;32:580-3. (Pubitemid 32155258)
20. Vitek L, Novotny L, Sperl M, Holaj R, Spacil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006;21:408-14. (Pubitemid 44617309)
21. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995;41:1504-8.
22. Hunt SC, Kronenberg F, Eckfeldt JH, Hopkins PN, Myers RH, Heiss G. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 2001;154:747-54.
23. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001;87:1196-200; A4, 7.
24. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003;228:568-71.
25. Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, Perrella MA. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J 2003;17:1759-61.
26. Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 2007;298:1398-400.
27. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovasc Risk 1996;3:459-63.
28. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, et al. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008;74:1197-201.
29. Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, Lin JL. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009;203:563-8.
30. Bhuiyan AR, Srinivasan SR, Chen W, Sultana A, Berenson GS. Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study. Metabolism 2008;57:612-6.
31. Andersson C, Weeke P, Fosbol EL, Brendorp B, Kober L, Coutinho W, et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009;58:1109-15.
32. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999;12:673-81.
33. Gullu H, Erdogan D, Tok D, Topcu S, Caliskan M, Ulus T, Muderrisoglu H. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol 2005;25:2289-94.
34. Hunt SC, Wu LL, Hopkins PN, Williams RR. Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees. Arterioscler Thromb Vasc Biol 1996;16:912-7.
35. Kronenberg F, Coon H, Gutin A, Abkevich V, Samuels ME, Ballinger DG, et al. A genome scan for loci influencing anti-atherogenic serum bilirubin levels. Eur J Hum Genet 2002;10:539-46.
36. Lin JP, Cupples LA, Wilson PW, Heard-Costa N, O'Donnell CJ. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am J Hum Genet 2003;72:1029-34.
37. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RP, Jansen PL, Chowdhury JR. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 1992;15:941-7.
38. Labrune P, Myara A, Hadchouel M, Ronchi F, Bernard O, Trivin F, et al. Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of 14 cases. Hum Genet 1994;94:693-7.
39. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994;94:2385-91. (Pubitemid 24379612)
40. Sampietro M, Iolascon A. Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes. Haematologica 1999;84:150-7. (Pubitemid 29479662)
41. Bosma P, Chowdhury JR, Jansen PH. Genetic inheritance of Gilbert's syndrome. Lancet 1995;346:314-5.
42. Black M, Billing BH. Hepatic bilirubin UDPglucuronyl transferase activity in liver disease and Gilbert's syndrome. N Engl J Med 1969;280:1266-71.
43. Lin JP, Schwaiger JP, Cupples LA, O'Donnell CJ, Zheng G, Schoenborn V, et al. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels: the Framingham Heart Study. Atherosclerosis 2009;206:228-33.
44. Hong AL, Huo D, Kim HJ, Niu Q, Fackenthal DL, Cummings SA, et al. UDP-glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos 2007;35:1254-61. (Pubitemid 47121764)
45. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002;292:492-7. (Pubitemid 34694291)
46. Lin Z, Fontaine J, Watchko JF. Coexpression of gene polymorphisms involved in bilirubin production and metabolism. Pediatrics 2008;122:e156-62.
47. Lingenhel A, Kollerits B, Schwaiger JP, Hunt SC, Gress R, Hopkins PN, et al. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp Gerontol 2008;43:1102-7.
48. Maruo Y, D'Addario C, Mori A, Iwai M, Takahashi H, Sato H, Takeuchi Y. Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum Genet 2004;115:525-6. (Pubitemid 39567280)
49. Martin JF, Vierling JM, Wolkoff AW, Scharschmidt BF, Vergalla J, Waggoner JG, Berk PD. Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology 1976;70:385-91.
50. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40. (Pubitemid 38971233)
51. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73:554-65. (Pubitemid 37249126)
52. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002;54:1343-52.
53. Kim RB. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin Pharmacol Ther 2004;75:381-5.
54. Huang CS, Huang MJ, Lin MS, Yang SS, Teng HC, Tang KS. Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet Genomics 2005;15:43-50.
55. Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol 2007;34:1240-4. (Pubitemid 350013247)
56. Chen YH, Chau LY, Lin MW, Chen LC, Yo MH, Chen JW, Lin SJ. Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 2004;25:39-47.
57. Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002;22:1680-5.
58. Ono K, Goto Y, Takagi S, Baba S, Tago N, Nonogi H, Iwai N. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis 2004;173:315-9. (Pubitemid 38469802)
59. Ono K, Mannami T, Iwai N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J Hypertens 2003;21:1497-503. (Pubitemid 36994128)
60. Schillinger M, Exner M, Mlekusch W, Ahmadi R, Rumpold H, Mannhalter C, et al. Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. J Endovasc Ther 2002;9:385-94.
61. Schillinger M, Exner M, Mlekusch W, Domanovits H, Huber K, Mannhalter C, et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 2002;106:131-6. (Pubitemid 35245237)
62. Endler G, Exner M, Schillinger M, Marculescu R, Sunder-Plassmann R, Raith M, et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. Thromb Haemost 2004;91:155-61. (Pubitemid 38111232)
63. Li P, Elrayess MA, Gomma AH, Palmen J, Hawe E, Fox KM, Humphries SE. The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting. Chin Med J (Engl) 2005;118:1525-32. (Pubitemid 41404202)
64. Lublinghoff N, Winkler K, Winkelmann BR, Seelhorst U, Wellnitz B, Boehm BO, et al. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med Genet 2009;10:36.
65. Ryter SW, Choi AM. Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy. Am J Respir Cell Mol Biol 2009;41:251-60.
66. Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, et al. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol Res 2004;30:91-5. (Pubitemid 41115270)
67. Lin R, Wang X, Wang Y, Zhang F, Fu W, Yu T, et al. Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations. Hum Mutat 2009;30:609-15.
68. Lin R, Wang Y, Fu W, Zhang D, Zheng H, Yu T, et al. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics 2009;19:310-8.
69. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009;18:2700-10.
70. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33. (Pubitemid 351560529)
71. Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009;18:2711-8.
72. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429-45.
73. Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem 2003;49:1180-1. (Pubitemid 36751106)
74. Gajdos V, Petit FM, Perret C, Mollet-Boudjemline A, Colin P, Capel L, et al. Further evidence that the UGT1A1*28 allele is not associated with coronary heart disease: the ECTIM Study. Clin Chem 2006;52:2313-4. (Pubitemid 44925016)
75. Hsieh CJ, Chen MJ, Liao YL, Liao TN. Polymorphisms of the uridine-diphosphoglucuronosyltransferase 1A1 gene and coronary artery disease. Cell Mol Biol Lett 2008;13:1-10. (Pubitemid 351679939)
76. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114:1476-81. (Pubitemid 44527002)
77. McCarty MF. 'Iatrogenic Gilbert syndrome': a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007;69:974-94.
78. Murthy GD, Byron D, Shoemaker D, Visweswaraiah H, Pasquale D. The utility of rifampin in diagnosing Gilbert's syndrome. Am J Gastroenterol 2001;96:1150-4. (Pubitemid 32319152)
79. White GL Jr, Nelson JA, Pedersen DM, Ash KO. Fasting and gender (and altitude?) influence reference intervals for serum bilirubin in healthy adults. Clin Chem 1981;27:1140-2.